bioRxiv Science⌕ Search

Biology subjects

Profico, D. C.

Publications and source records attributed to Profico, D. C..

2 recordsLinked to original sources

Intercellular Transfer of PTBP1 Drives Human Neural Stem Cell Fate

During fetal brain development, temporally defined alternative splicing (AS) programs control human neural stem cell (hNSC) self-renewal and differentiation, thereby regulating neurogenesis and gliogenesis. Polypyrimidine tract-binding protein 1 (PTBP1) is a master regulator of AS during neurogenesis; however, its functional role and dynamics in hNSCs remain largely unexplored. Here, we investigate the cellular and molecular functions, nucleocytoplasmic distribution, and intercellular trafficking of PTBP1 in primary hNSCs. We found that PTBP1 knockdown (KD) alters self-renewal capacity, mitochondrial dynamics and membrane potential, lipid droplet abundance, and PTBP2 expression. RNA sequencing analysis revealed that PTBP1 depletion affects the expression profiling of hundreds of coding and non-coding genes, collectively orchestrating a neuronal differentiation program. Super-resolution {tau}-STED microscopy and live-cell imaging demonstrated that PTBP1 localizes not only to the nucleus but also to the cytoplasm, tunneling nanotubes (TNTs), migrasomes, and extracellular vesicles (EVs). Co-culture experiments and EV uptake assays showed that cytosolic PTBP1 can be transferred between hNSCs and delivered to the nuclei of recipient cells via TNTs and EVs. Moreover, EVs were found to contain specific and previously uncharacterized PTBP1 isoforms and were efficiently transferred to PTBP1-KD cells, rescuing their proliferative capacity. Analysis of the mouse brain reveals the presence of PTBP1 in the V-SVZ and within TNT-like structures connecting NSCs, suggesting a role for TNT-mediated PTBP1 trafficking in vivo. Together, these findings uncover previously unrecognized roles for PTBP1 in hNSCs and provide the first evidence that PTBP1 can be transferred between hNSCs via TNTs and EVs, revealing a novel mechanism by which hNSCs may regulate fetal neurogenesis. Graphical AbstractA: PTBP1 regulates hNSC fate by controlling cell proliferation, lipid droplet dynamics, mitochondrial function, and post-transcriptional programs involved in neuronal commitment. B: Cytosolic PTBP1 is transferred between hNSCs via tunneling nanotubes (TNTs) and extracellular vesicles (EVs). Abbreviations: LV, lateral ventricle; aRG, apical radial glial cells; bRG, basal radial glial cells; V-SVZ, ventricular-subventricular zone; EVs, extracellular vesicles; TNTs, tunneling nanotubes.

neuroscience↗

Challenges and promises in optimising a non-clinical protocol of intracerebroventricular human neural stem cell transplantation in ALS

Background and aimsNeural stem cell (NSC) transplantation holds promising therapeutic potential for neurodegenerative disorders like amyotrophic lateral sclerosis (ALS). However, pre-clinical studies and early-phase clinical trials have faced challenges hindering the effective clinical translation of this approach. Crucial hurdles include the side-effects of prolonged immunosuppression, concerns regarding cell origin and transplantation dosage, identification of the most appropriate therapeutic window, and invasiveness of surgical procedures. Here, we show challenges and promises in optimizing a non-clinical protocol to assess safety and efficacy of human NSC (hNSC) intracerebroventricular (ICV) transplantation for ALS. MethodsWe evaluated the safety of administering up to 1x106 hNSCs in immunodeficient mice and assessed their potential efficacy in reducing ALS hallmarks employing the SOD1G93A mouse model. Both, transient (15 days) and prolonged immunosuppression regimens, at low (15 mg/kg) and high (30 mg/kg) doses, were tested along with two different cell dosages (3x105 and 1x106). ResultsBilateral ICV injection of up to 1x106 hNSCs proved to be safe, with no evidence of tumor formation. At 40 days post-transplantation, hNSCs induced a trend toward delaying motor decline and reducing spinal cord (SC) microgliosis when transplanted under prolonged high-dose (30 mg/kg) immunosuppression. ConclusionsOur study suggests that: (i) a bilateral ICV transplantation of 1x106 hNSCs is safe and non-tumorigenic in immunodeficient hosts; (ii) sustained high-dose immunosuppression is essential for ensuring cell survival in immunocompetent mice; and (iii) hNSC transplantation may provide therapeutic benefits in ALS by delaying motor decline and reducing microgliosis. This study also highlights persisting hurdles that need to be further addressed, such as the aggressive murine immune response to exogenous cells.

neuroscience↗